ArriVent BioPharma (AVBP) Expected to Announce Earnings on Wednesday

ArriVent BioPharma (NASDAQ:AVBP) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 14th. Analysts expect ArriVent BioPharma to post earnings of ($0.66) per share for the quarter.

ArriVent BioPharma (NASDAQ:AVBP) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.18. On average, analysts expect ArriVent BioPharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Trading Up 1.1%

NASDAQ:AVBP opened at $19.97 on Monday. ArriVent BioPharma has a 12 month low of $15.47 and a 12 month high of $36.37. The company has a market capitalization of $679.88 million, a P/E ratio of -7.77 and a beta of 1.47. The firm has a fifty day simple moving average of $19.53 and a 200-day simple moving average of $24.84.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Guggenheim initiated coverage on ArriVent BioPharma in a research note on Monday, March 10th. They set a “buy” rating and a $45.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 target price on shares of ArriVent BioPharma in a research note on Friday, March 7th. Finally, B. Riley assumed coverage on ArriVent BioPharma in a research report on Thursday, March 20th. They set a “buy” rating and a $37.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, ArriVent BioPharma presently has an average rating of “Buy” and a consensus target price of $39.00.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.